<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>China Sxt Pharmaceuticals, Inc. — News on 6ix</title>
<link>https://6ix.com/company/china-sxt-pharmaceuticals-inc</link>
<description>Latest news and press releases for China Sxt Pharmaceuticals, Inc. on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Mon, 23 Mar 2026 04:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/china-sxt-pharmaceuticals-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835c65578dffbe2df11afaf.webp</url>
<title>China Sxt Pharmaceuticals, Inc.</title>
<link>https://6ix.com/company/china-sxt-pharmaceuticals-inc</link>
</image>
<item>
<title>China SXT Pharmaceuticals, Inc. Announces Share Re-classification</title>
<link>https://6ix.com/company/china-sxt-pharmaceuticals-inc/news/china-sxt-pharmaceuticals-inc-announces-share-re-classification</link>
<guid isPermaLink="true">https://6ix.com/company/china-sxt-pharmaceuticals-inc/news/china-sxt-pharmaceuticals-inc-announces-share-re-classification</guid>
<pubDate>Mon, 23 Mar 2026 04:00:00 GMT</pubDate>
<description>TAIZHOU, China, March 23, 2026 (GLOBE NEWSWIRE) -- China SXT Pharmaceutics, Inc. (Nasdaq: SXTC) (the “Company” or “SXTC”), a specialty pharmaceutical company</description>
</item>
<item>
<title>China SXT Pharmaceuticals, Inc. Announces Share Consolidation</title>
<link>https://6ix.com/company/china-sxt-pharmaceuticals-inc/news/china-sxt-pharmaceuticals-inc-announces-140000583</link>
<guid isPermaLink="true">https://6ix.com/company/china-sxt-pharmaceuticals-inc/news/china-sxt-pharmaceuticals-inc-announces-140000583</guid>
<pubDate>Fri, 30 Jan 2026 14:00:00 GMT</pubDate>
<description>TAIZHOU, China, Jan. 30, 2026 (GLOBE NEWSWIRE) -- China SXT Pharmaceutics, Inc. (Nasdaq: SXTC) (the “Company” or “SXTC”), a specialty pharmaceutical company focusing on the research, development, manufacturing, marketing, and sales of Traditional Chinese Medicine Pieces (“TCMPs”), including Advanced TCMPs (Directly-Oral TCMP and After-Soaking-Oral TCMP), fine TCMPs, regular TCMPs, and TCM Homologous Supplements (“TCMHS”), today announced that it will effect a share consolidation of its ordinary</description>
</item>
<item>
<title>CHINA SXT PHARMACEUTICALS, INC. ANNOUNCES STRATEGIC INITIATIVE TO APPLY AI TECHNOLOGY ACROSS THE TCM SUPPLY CHAIN</title>
<link>https://6ix.com/company/china-sxt-pharmaceuticals-inc/news/china-sxt-pharmaceuticals-inc-announces-140000189</link>
<guid isPermaLink="true">https://6ix.com/company/china-sxt-pharmaceuticals-inc/news/china-sxt-pharmaceuticals-inc-announces-140000189</guid>
<pubDate>Thu, 15 Jan 2026 14:00:00 GMT</pubDate>
<description>TAIZHOU, China, Jan. 15, 2026 (GLOBE NEWSWIRE) -- China SXT Pharmaceuticals, Inc. (NASDAQ: SXTC) (“China SXT” or the “Company”), a specialty pharmaceutical company focusing on the research, development, manufacturing, marketing, and sales of Traditional Chinese Medicine Pieces (“TCMPs”), including Advanced TCMPs (Directly-Oral TCMP and After-Soaking-Oral TCMP), fine TCMPs, regular TCMPs, and TCM Homologous Supplements (“TCMHS”), today announced as part of its Artificial Intelligence (AI) Insight</description>
</item>
<item>
<title>China SXT Pharmaceuticals Inc. Announces $10 Million Registered Direct Offering</title>
<link>https://6ix.com/company/china-sxt-pharmaceuticals-inc/news/china-sxt-pharmaceuticals-inc-announces-195000427</link>
<guid isPermaLink="true">https://6ix.com/company/china-sxt-pharmaceuticals-inc/news/china-sxt-pharmaceuticals-inc-announces-195000427</guid>
<pubDate>Fri, 09 Jan 2026 19:50:00 GMT</pubDate>
<description>TAIZHOU, China, Jan. 09, 2026 (GLOBE NEWSWIRE) -- China SXT Pharmaceuticals Inc. (NASDAQ: SXTC) (the “Company”), today announced that it has entered into a definitive agreement with a single investor for the purchase and sale of an aggregate of 66,666,666 Class A ordinary shares of the company, no par value per share (the “Shares”) (or pre-funded warrants in lieu thereof), at a purchase price of $0.15 per share in a registered direct offering. The purchase price for each pre-funded warrant is id</description>
</item>
<item>
<title>CHINA SXT PHARMACEUTICALS, INC. ANNOUNCES STRATEGIC AI INSIGHTS INITIATIVE TO OPTIMIZE TRADITIONAL CHINESE MEDICINE PORTFOLIO, ENHANCE MARKET ANALYSIS AND EXPLORE AI-SUPPORTED CLINIC DEPLOYMENT</title>
<link>https://6ix.com/company/china-sxt-pharmaceuticals-inc/news/china-sxt-pharmaceuticals-inc-announces-142000787</link>
<guid isPermaLink="true">https://6ix.com/company/china-sxt-pharmaceuticals-inc/news/china-sxt-pharmaceuticals-inc-announces-142000787</guid>
<pubDate>Thu, 08 Jan 2026 14:20:00 GMT</pubDate>
<description>TAIZHOU, China, Jan. 08, 2026 (GLOBE NEWSWIRE) -- China SXT Pharmaceuticals, Inc. (NASDAQ: SXTC) ("China SXT" or the "Company"), a specialty pharmaceutical company focusing on the research, development, manufacturing, marketing, and sales of Traditional Chinese Medicine Pieces ("TCMPs"), including Advanced TCMPs (Directly-Oral TCMP and After-Soaking-Oral TCMP), fine TCMPs, regular TCMPs, and TCM Homologous Supplements ("TCMHS"), today announced the launch of a Strategic Artificial Intelligence (</description>
</item>
<item>
<title>China SXT Pharmaceuticals Has Regained Compliance with Nasdaq’s Minimum Bid Price Deficiency</title>
<link>https://6ix.com/company/china-sxt-pharmaceuticals-inc/news/china-sxt-pharmaceuticals-regained-compliance-123000099</link>
<guid isPermaLink="true">https://6ix.com/company/china-sxt-pharmaceuticals-inc/news/china-sxt-pharmaceuticals-regained-compliance-123000099</guid>
<pubDate>Mon, 17 Mar 2025 12:30:00 GMT</pubDate>
<description>TAIZHOU, China, March 17, 2025 (GLOBE NEWSWIRE) -- China SXT Pharmaceuticals, Inc. (Nasdaq: SXTC) (the “Company”), a specialty pharmaceutical company focusing on the research, development, manufacturing, marketing, and sales of Traditional Chinese Medicine Pieces (“TCMPs”), including Advanced TCMPs (Directly-Oral TCMP and After-Soaking-Oral TCMP), fine TCMPs, regular TCMPs, and TCM Homologous Supplements (“TCMHS”), today announced that the Company received a written notification (the “Compliance</description>
</item>
<item>
<title>China SXT Pharmaceuticals, Inc. Received Nasdaq Notification Letter Regarding Bid Price Deficiency</title>
<link>https://6ix.com/company/china-sxt-pharmaceuticals-inc/news/china-sxt-pharmaceuticals-inc-received-nasdaq-notification-letter-regarding-bid-price-deficiency</link>
<guid isPermaLink="true">https://6ix.com/company/china-sxt-pharmaceuticals-inc/news/china-sxt-pharmaceuticals-inc-received-nasdaq-notification-letter-regarding-bid-price-deficiency</guid>
<pubDate>Mon, 07 Oct 2024 04:00:00 GMT</pubDate>
<description>Jiangsu, China, , Oct. 07, 2024 (GLOBE NEWSWIRE) -- China SXT Pharmaceuticals, Inc. (“SXTC” or the “Company”), (NASDAQ: SXTC) announced today that on October</description>
</item>
<item>
<title>China SXT Pharmaceuticals, Inc. Regained Compliance with Nasdaq’s Minimum Bid Price Rule</title>
<link>https://6ix.com/company/china-sxt-pharmaceuticals-inc/news/china-sxt-pharmaceuticals-inc-regained-compliance-with-nasdaqs-minimum-bid-price-rule</link>
<guid isPermaLink="true">https://6ix.com/company/china-sxt-pharmaceuticals-inc/news/china-sxt-pharmaceuticals-inc-regained-compliance-with-nasdaqs-minimum-bid-price-rule</guid>
<pubDate>Thu, 26 Oct 2023 04:00:00 GMT</pubDate>
<description>TAIZHOU, China, Oct. 26, 2023 (GLOBE NEWSWIRE) -- China SXT Pharmaceuticals, Inc. ("SXTC" or the "Company"), (NASDAQ: SXTC), a specialty pharmaceutical</description>
</item>
<item>
<title>China SXT Pharmaceuticals Announces One-for-Twenty-five Reverse Stock Split</title>
<link>https://6ix.com/company/china-sxt-pharmaceuticals-inc/news/china-sxt-pharmaceuticals-announces-one-for-twenty-five-reverse-stock-split</link>
<guid isPermaLink="true">https://6ix.com/company/china-sxt-pharmaceuticals-inc/news/china-sxt-pharmaceuticals-announces-one-for-twenty-five-reverse-stock-split</guid>
<pubDate>Wed, 04 Oct 2023 04:00:00 GMT</pubDate>
<description>Ordinary Shares Will Begin Trading on a Split-Adjusted Basis on October 5, 2023 TAIZHOU, China, Oct. 04, 2023 (GLOBE NEWSWIRE) -- China SXT Pharmaceuticals,</description>
</item>
<item>
<title>China SXT Pharmaceuticals, Inc. Receives 180-day Extension from Nasdaq to Meet Minimum Bid Price Rule</title>
<link>https://6ix.com/company/china-sxt-pharmaceuticals-inc/news/china-sxt-pharmaceuticals-inc-receives-180-day-extension-from-nasdaq-to-meet-minimum-bid-price-rule</link>
<guid isPermaLink="true">https://6ix.com/company/china-sxt-pharmaceuticals-inc/news/china-sxt-pharmaceuticals-inc-receives-180-day-extension-from-nasdaq-to-meet-minimum-bid-price-rule</guid>
<pubDate>Wed, 10 May 2023 04:00:00 GMT</pubDate>
<description>TAIZHOU, China, May 10, 2023 (GLOBE NEWSWIRE) -- China SXT Pharmaceuticals, Inc. ("SXTC" or the "Company"), (NASDAQ: SXTC), a specialty pharmaceutical company</description>
</item>
<item>
<title>China SXT Pharmaceuticals, Inc. Announces 1 for 20 Reverse Share Split</title>
<link>https://6ix.com/company/china-sxt-pharmaceuticals-inc/news/china-sxt-pharmaceuticals-inc-announces-1-for-20-reverse-share-split</link>
<guid isPermaLink="true">https://6ix.com/company/china-sxt-pharmaceuticals-inc/news/china-sxt-pharmaceuticals-inc-announces-1-for-20-reverse-share-split</guid>
<pubDate>Wed, 18 May 2022 04:00:00 GMT</pubDate>
<description>TAIZHOU, China, May 18, 2022 (GLOBE NEWSWIRE) -- China SXT Pharmaceuticals, Inc. (NASDAQ: SXTC) ("China SXT" or the "Company"), a specialty pharmaceutical</description>
</item>
<item>
<title>China SXT Pharmaceuticals, Inc. Enters into Securities Purchase Agreement to Issue a 6% Convertible Promissory Note in the Original Principal Amount of $2.8 Million</title>
<link>https://6ix.com/company/china-sxt-pharmaceuticals-inc/news/china-sxt-pharmaceuticals-inc-enters-into-securities-purchase-agreement-to-issue-a-6percent-convertible-promissory-note-in-the-original-principal-amount-of-dollar28-million</link>
<guid isPermaLink="true">https://6ix.com/company/china-sxt-pharmaceuticals-inc/news/china-sxt-pharmaceuticals-inc-enters-into-securities-purchase-agreement-to-issue-a-6percent-convertible-promissory-note-in-the-original-principal-amount-of-dollar28-million</guid>
<pubDate>Mon, 14 Mar 2022 04:00:00 GMT</pubDate>
<description>TAIZHOU, China, March 14, 2022 (GLOBE NEWSWIRE) -- China SXT Pharmaceuticals, Inc. ("SXTC" or the "Company"), (NASDAQ: SXTC), a specialty pharmaceutical</description>
</item>
<item>
<title>China SXT Pharmaceuticals, Inc. Announces Successful Closing of $4.1 Million Follow-on Underwritten Offering of Ordinary Shares and Pre-Funded Warrants With Simultaneous Exercise of the Over-Allotment</title>
<link>https://6ix.com/company/china-sxt-pharmaceuticals-inc/news/china-sxt-pharmaceuticals-inc-announces-successful-closing-of-dollar41-million-follow-on-underwritten-offering-of-ordinary-shares-and-pre-funded-warrants-with-simultaneous-exercise-of-the-over-allotment</link>
<guid isPermaLink="true">https://6ix.com/company/china-sxt-pharmaceuticals-inc/news/china-sxt-pharmaceuticals-inc-announces-successful-closing-of-dollar41-million-follow-on-underwritten-offering-of-ordinary-shares-and-pre-funded-warrants-with-simultaneous-exercise-of-the-over-allotment</guid>
<pubDate>Thu, 20 Jan 2022 05:00:00 GMT</pubDate>
<description>TAIZHOU, China, Jan. 20, 2022 (GLOBE NEWSWIRE) -- China SXT Pharmaceuticals, Inc. ("SXTC" or the "Company"), (NASDAQ: SXTC), a specialty pharmaceutical</description>
</item>
<item>
<title>China SXT Pharmaceuticals, Inc. Prices $3.5 Million Underwritten Public Offering of Ordinary Shares and Pre-Funded Warrants to Purchase Ordinary Shares</title>
<link>https://6ix.com/company/china-sxt-pharmaceuticals-inc/news/china-sxt-pharmaceuticals-inc-prices-dollar35-million-underwritten-public-offering-of-ordinary-shares-and-pre-funded-warrants-to-purchase-ordinary-shares</link>
<guid isPermaLink="true">https://6ix.com/company/china-sxt-pharmaceuticals-inc/news/china-sxt-pharmaceuticals-inc-prices-dollar35-million-underwritten-public-offering-of-ordinary-shares-and-pre-funded-warrants-to-purchase-ordinary-shares</guid>
<pubDate>Tue, 18 Jan 2022 05:00:00 GMT</pubDate>
<description>TAIZHOU, China, Jan. 18, 2022 (GLOBE NEWSWIRE) -- China SXT Pharmaceuticals, Inc. ("SXTC" or the "Company"), (NASDAQ: SXTC), a specialty pharmaceutical</description>
</item>
<item>
<title>China SXT Pharmaceuticals, Inc. Adds Newly Developed Kuihuapan and Zhudanfen Advanced TCMP Products, and Announces the Expected Continuous Growth of Its Production Capacity of Luxuejin</title>
<link>https://6ix.com/company/china-sxt-pharmaceuticals-inc/news/china-sxt-pharmaceuticals-inc-adds-newly-developed-kuihuapan-and-zhudanfen-advanced-tcmp-products-and-announces-the-expected-continuous-growth-of-its-production-capacity-of-luxuejin</link>
<guid isPermaLink="true">https://6ix.com/company/china-sxt-pharmaceuticals-inc/news/china-sxt-pharmaceuticals-inc-adds-newly-developed-kuihuapan-and-zhudanfen-advanced-tcmp-products-and-announces-the-expected-continuous-growth-of-its-production-capacity-of-luxuejin</guid>
<pubDate>Fri, 14 Jan 2022 05:00:00 GMT</pubDate>
<description>TAIZHOU, China, Jan. 14, 2022 /PRNewswire/ -- China SXT Pharmaceuticals, Inc. (NASDAQ: SXTC) ("China SXT" or the "Company"), a specialty pharmaceutical</description>
</item>
<item>
<title>China SXT Pharmaceuticals, Inc. Announces Proposed Underwritten Public Offering of Ordinary Shares and Pre-Funded Warrants to Purchase Ordinary Shares</title>
<link>https://6ix.com/company/china-sxt-pharmaceuticals-inc/news/china-sxt-pharmaceuticals-inc-announces-proposed-underwritten-public-offering-of-ordinary-shares-and-pre-funded-warrants-to-purchase-ordinary-shares</link>
<guid isPermaLink="true">https://6ix.com/company/china-sxt-pharmaceuticals-inc/news/china-sxt-pharmaceuticals-inc-announces-proposed-underwritten-public-offering-of-ordinary-shares-and-pre-funded-warrants-to-purchase-ordinary-shares</guid>
<pubDate>Fri, 14 Jan 2022 05:00:00 GMT</pubDate>
<description>TAIZHOU, China, Jan. 14, 2022 (GLOBE NEWSWIRE) -- China SXT Pharmaceuticals, Inc. ("SXTC" or the "Company"), (NASDAQ: SXTC), a specialty pharmaceutical</description>
</item>
<item>
<title>China SXT Pharmaceuticals, Inc. Obtained a New Pharmaceutical Manufacturing Permit and Passed Its GMP Compliance-Inspection</title>
<link>https://6ix.com/company/china-sxt-pharmaceuticals-inc/news/china-sxt-pharmaceuticals-inc-obtained-a-new-pharmaceutical-manufacturing-permit-and-passed-its-gmp-compliance-inspection</link>
<guid isPermaLink="true">https://6ix.com/company/china-sxt-pharmaceuticals-inc/news/china-sxt-pharmaceuticals-inc-obtained-a-new-pharmaceutical-manufacturing-permit-and-passed-its-gmp-compliance-inspection</guid>
<pubDate>Mon, 18 Oct 2021 04:00:00 GMT</pubDate>
<description>TAIZHOU, China, Oct. 18, 2021 /PRNewswire/ -- China SXT Pharmaceuticals, Inc. (NASDAQ: SXTC) ("China SXT" or the "Company"), a specialty pharmaceutical</description>
</item>
<item>
<title>China SXT Pharmaceuticals, Inc. Announces 1 for 4 Reverse Share Split</title>
<link>https://6ix.com/company/china-sxt-pharmaceuticals-inc/news/china-sxt-pharmaceuticals-inc-announces-1-for-4-reverse-share-split</link>
<guid isPermaLink="true">https://6ix.com/company/china-sxt-pharmaceuticals-inc/news/china-sxt-pharmaceuticals-inc-announces-1-for-4-reverse-share-split</guid>
<pubDate>Fri, 19 Feb 2021 05:00:00 GMT</pubDate>
<description>TAIZHOU, China, Feb. 19, 2021 /PRNewswire/ -- China SXT Pharmaceuticals, Inc. (NASDAQ: SXTC) ("China SXT" or the "Company"), a specialty pharmaceutical</description>
</item>
<item>
<title>China SXT Pharmaceuticals, Inc. Enters into Non-Binding LOI to Acquire Jiangsu Renji Pharmaceutical Chain Co., Ltd.</title>
<link>https://6ix.com/company/china-sxt-pharmaceuticals-inc/news/china-sxt-pharmaceuticals-inc-enters-into-non-binding-loi-to-acquire-jiangsu-renji-pharmaceutical-chain-co-ltd</link>
<guid isPermaLink="true">https://6ix.com/company/china-sxt-pharmaceuticals-inc/news/china-sxt-pharmaceuticals-inc-enters-into-non-binding-loi-to-acquire-jiangsu-renji-pharmaceutical-chain-co-ltd</guid>
<pubDate>Thu, 11 Feb 2021 05:00:00 GMT</pubDate>
<description>TAIZHOU, China, Feb. 11, 2021 /PRNewswire/ -- China SXT Pharmaceuticals, Inc. (NASDAQ: SXTC) ("China SXT" or the "Company") announced today that it has</description>
</item>
<item>
<title>China SXT Pharmaceuticals, Inc. Announces That It Received a Grant Supported by City Government</title>
<link>https://6ix.com/company/china-sxt-pharmaceuticals-inc/news/china-sxt-pharmaceuticals-inc-announces-that-it-received-a-grant-supported-by-city-government</link>
<guid isPermaLink="true">https://6ix.com/company/china-sxt-pharmaceuticals-inc/news/china-sxt-pharmaceuticals-inc-announces-that-it-received-a-grant-supported-by-city-government</guid>
<pubDate>Mon, 16 Mar 2020 04:00:00 GMT</pubDate>
<description>TAIZHOU, China, March 16, 2020 /PRNewswire/ -- China SXT Pharmaceuticals, Inc. (NASDAQ: SXTC) ("China SXT" or the "Company"), a specialty pharmaceutical</description>
</item>
</channel>
</rss>